Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real‑world effectiveness and safety of cefiderocol in critically ill patients with MDR Gram‑negative infections: Results from a retrospective study

22 Jul 2025

Abstract excerpt

The increasing prevalence of multidrug‑resistant (MDR) Gram‑negative bacteria, particularly Acinetobacter baumannii (A. baumannii), represents a major clinical challenge, especially in critically ill patients. Cefiderocol, a siderophore cephalosporin, has emerged as a promising therapeutic option for infections caused by carbapenem‑resistant organisms. The present study aimed to evaluate the real‑life efficacy...

Topics

Join the communities discussing this publication.

Antibiotic Resistance in Bacteria
Antibiotics Pharmacokinetics and Efficacy
Pneumocystis jirovecii pneumonia detection and treatment

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 40756900
DOI: 10.3892/br.2025.2034

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real‑world effectiveness and safety of cefiderocol in critically ill patients with MDR Gram‑negative infections: Results from a retrospective studyPMID 40756900Read ↗

Effectiveness and Safety of Cefiderocol in Clinical Practice for Treatment of Patients with Gram-Negative Bacterial Infections: US Interim Results of the PROVE StudySemantic proximity Read ↗

Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant Gram-negative bacteria: CEFI-IDSemantic proximity Read ↗

Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging DataSemantic proximity Read ↗

In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitalsSemantic proximity Read ↗

An Overview of Cefiderocol’s Therapeutic Potential and Underlying Resistance MechanismsSemantic proximity Read ↗

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance ProgramSemantic proximity Read ↗

Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumanniiSemantic proximity Read ↗

Cefiderocol: An Overview of Its in-vitro and in-vivo Activity and Underlying Resistant MechanismsSemantic proximity Read ↗

Cefiderocol in Combating Carbapenem-Resistant Acinetobacter baumannii: Action and ResistanceSemantic proximity Read ↗

Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative BacteriaSemantic proximity Read ↗

Cefto-Reallife Study: Real World Data on the Use of Ceftobiprole in a Multicenter Spanish CohortSemantic proximity Read ↗

Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical TrialsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.